510(k) device
Axoguard HA+ Nerve Protector (AGHA12)
Axogen Corporation · Cuff, Nerve (JXI, Class II) · First FDA decision Apr 7, 2023, newest Oct 12, 2023Peripheral neuropathy and nerve injury
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
3
Naming "Axoguard HA+"
MAUDE reports
45
Brand "Axoguard HA+", since 2015
PubMed studies
0
Mentioning "Axoguard HA+"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Axoguard HA+ Nerve Protector (AGHA12)
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K231708 · Decided Oct 12, 2023 · 122 days after receipt
Device type: Cuff, Nerve (JXI) · Neurology & Neurosurgery
K223640 · Decided Apr 7, 2023 · 123 days after receipt
Device type: Cuff, Nerve (JXI) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Vagus Nerve Stimulation (VNS)National determinationOn the books160.18Updated Nov 5, 2026
- Vagus Nerve Stimulation for Treatment of Resistant Depression (TRD)National analysisReview closedCAG-00313RUpdated Sep 24, 2026
- Vagus Nerve Stimulation (VNS) for Treatment Resistant Depression (TRD)National analysisReview closedCAG-00313R2Updated Sep 24, 2026
- Transcutaneous Electrical Nerve Stimulation for Chronic Low Back PainNational analysisReview closedCAG-00429NUpdated Sep 24, 2026
- Cavernous Nerves Electrical Stimulation with Penile PlethysmographyNational analysisReview closedCAG-00311NUpdated Sep 17, 2026
- Sacral Nerve Stimulation for Urge Urinary IncontinenceNational analysisReview closedCAG-00058NUpdated Sep 15, 2026
- Electrodiagnostic Sensory Nerve Conduction ThresholdNational analysisReview closedCAG-00106RUpdated Sep 14, 2026
- Electrodiagnostic Sensory Nerve Conduction ThresholdNational analysisReview closedCAG-00106NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Axoguard HA+", any status and sponsor, newest update first.
- Hyaluronic Acid Barrier in ParotidectomyNot yet recruiting
Milton S. Hershey Medical CenterAcademic, hospital or other
NCT07941011 · 20 participants (planned) · Start Jan 1, 2027 · Primary completion Jan 31, 2029
Device: Axoguard HA+ Nerve Protector · For: Parotidectomy, Patient-reported Outcomes; Parotid Cancer; Parotid Gland Tumor and 2 more
Axogen CorporationNot on our public-company list
NCT06117501 · 19 participants · Start Oct 19, 2023 · Primary completion Aug 17, 2026
Device: Axoguard HA+ Nerve Protector™ · For: Recurrent Cubital Tunnel Syndrome; Recalcitrant Cubital Tunnel Syndrome
Sites: Tampa, Florida; Savannah, Georgia; Indianapolis, Indiana · 7 sites in all
- Axoguard HA Plus Nerve Protector to Reduce Post-operative Neck and Shoulder Dysfunction in Patients Undergoing Neck DissectionActive, not recruiting
Matthew SpectorAcademic, hospital or other
NCT07283861 · 90 participants (planned) · Start Dec 9, 2025 · Primary completion Jan 2027
Device: Spinal Accessory Nerve Protection utilizing Axoguard HA+ · For: Head and Neck Cancer; Neck Dissection
Sites: Pittsburgh, Pennsylvania
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Axoguard HA+", and for the whole product code for context.
This brand
45 reports: 0 malfunction, 45 injury, 0 death
Whole product code JXI
127 reports: 19 malfunction, 106 injury, 0 death
Newest reports for this brand
3017860045-2026-00020 · Received Oct 15, 2026 · Event dated Sep 17, 2026
Device type: Cuff, Nerve (JXI)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Impaired Healing; Tissue Irritation
3017860045-2026-00019 · Received Oct 9, 2026 · Event dated Aug 19, 2026
Device type: Cuff, Nerve (JXI)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Medical Device Site Inflammation
3017860045-2026-00016 · Received Sep 25, 2026 · Event dated Aug 28, 2026
Device type: Cuff, Nerve (JXI)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Medical device site infection
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Axoguard HA+"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code JXI.
- VersaWrap Nerve Protector (VTP-2201)Alafair Biosciences · 510(k) 2025
- Neurolac(R) Nerve GuidePolyganics B.V. · 510(k) 2011
- Reaxon PlusMedovent GmbH · 510(k) 2018
- NeuraGen 3D Nerve Guide MatrixIntegra LifeSciences Corporation · 510(k) 2017
- Collagen Nerve WrapCollagen Matrix, Inc. · 510(k) 2006
- SILKBridgeKLISBio S.r.l. · 510(k) 2026
- NeuroSpan BridgeAuxilium Biotechnologies, Inc. · 510(k) 2026
- VersaCoat Nerve Protector (VTP-44G2)Alafair Biosciences · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.